Prime Capital Investment Advisors LLC Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Prime Capital Investment Advisors LLC acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, Holdings Channel.com reports. The firm acquired 3,287 shares of the company’s stock, valued at approximately $206,000.

Several other institutional investors and hedge funds have also made changes to their positions in CRSP. Price T Rowe Associates Inc. MD lifted its position in CRISPR Therapeutics by 158.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,014,551 shares of the company’s stock worth $183,194,000 after buying an additional 1,848,437 shares during the period. ARK Investment Management LLC lifted its position in CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after buying an additional 1,372,986 shares during the period. State Street Corp lifted its position in CRISPR Therapeutics by 228.8% during the second quarter. State Street Corp now owns 1,569,860 shares of the company’s stock worth $95,400,000 after buying an additional 1,092,384 shares during the period. BlackRock Inc. lifted its position in CRISPR Therapeutics by 79.2% during the first quarter. BlackRock Inc. now owns 2,278,774 shares of the company’s stock worth $143,038,000 after buying an additional 1,007,246 shares during the period. Finally, Vanguard Group Inc. lifted its position in CRISPR Therapeutics by 261.4% during the first quarter. Vanguard Group Inc. now owns 1,217,289 shares of the company’s stock worth $76,410,000 after buying an additional 880,463 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,801 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $78.26, for a total transaction of $219,206.26. Following the completion of the sale, the general counsel now owns 60,070 shares in the company, valued at approximately $4,701,078.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel James R. Kasinger sold 1,913 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71. Following the sale, the general counsel now owns 57,371 shares of the company’s stock, valued at approximately $4,570,747.57. The disclosure for this sale can be found here. Insiders sold a total of 134,410 shares of company stock worth $9,234,677 in the last 90 days. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Stock Performance

CRSP stock opened at $60.67 on Monday. CRISPR Therapeutics AG has a 1 year low of $37.55 and a 1 year high of $91.10. The firm has a market cap of $5.15 billion, a P/E ratio of -30.95 and a beta of 1.76. The stock has a 50-day simple moving average of $74.01 and a 200-day simple moving average of $63.21.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to analyst estimates of $148.72 million. During the same quarter last year, the business posted ($1.41) EPS. CRISPR Therapeutics’s quarterly revenue was up 3253.3% compared to the same quarter last year. On average, equities research analysts predict that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

Analysts Set New Price Targets

CRSP has been the topic of several recent analyst reports. TheStreet upgraded CRISPR Therapeutics from a “d+” rating to a “c” rating in a research report on Friday, February 23rd. Mizuho upped their price target on CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Wolfe Research began coverage on CRISPR Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating for the company. Barclays upped their price target on CRISPR Therapeutics from $61.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 22nd. Finally, Morgan Stanley upped their price target on CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research note on Monday, February 26th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and an average target price of $74.93.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.